Bacterial resistance to indiscriminate use of azithromycin versus Covid-19: an integrative review
DOI:
https://doi.org/10.33448/rsd-v11i1.25035Keywords:
Bacterial resistance; Antimicrobials; Covid-19; Azithromycin.Abstract
Recently a disease caused by a new corona virus, sars-cov2, was described as Covid-19, and it spread, getting a pandemic character, viral spread and consequent increase in the number of deaths worldwide, there was a Growing rise in the dissemination of prophylactic news, there was an increase in the curve of self-medication by individuals, in large part, influenced by false news made available on social media and in debates without scientific basis. In this sense, a drug that stands out is Azithromycin, an antibiotic of the azalide type, which was widely prescribed and used on a large scale by the general population. By using Azithromycin, due to its immunomodulating effect in a pathology that is essentially viral, it opens the door to an increase in bacterial resistance to this medication and its drug class. It is plausible to say that the indiscriminate use of this antibiotic, regardless of its intended function, increases the possibility of selecting resistant bacteria. Objective: Therefore, the objective was to describe bacterial resistance due to the indiscriminate use of Azithromycin compared to Covid-19. Material and Method: This was an integrative literature review from the LILACS, PUBMED/MEDELINE and SCIELO databases, between 2019 and 2021. 75 articles were identified, 10 of which were used in the preparation of the work. Results show that self-medication during this pandemic period, emphasizing the indiscriminate use of Azithromycin, in addition to emphasizing the factors that contribute to this practice, which contribute to the increase in bacterial resistance. Factors such as errors in medical indications, self-medication by the population and an ineffective inspection of the sale of antimicrobials, in pharmacies and drugstores, where these drugs are concentrated, contribute to bacterial multi-resistance. Conclusion: It is necessary to guide and clarify, both health professionals and the population, about bacterial resistance, as well as the correct and effective indication and use of antibiotics against infectious diseases.
References
Almeida, F. B., Cabral, S. A. A. O., Alencar, M. C. B., Figueiredo, C. H. A., Silveira, D. C., & Farias, W. K. A. (2010). Atenção farmacêutica em análises da dispensação de antimicrobianos em farmácia. Revista Brasileira de Educação e Saúde. 5(4),23-29. doi.org/10.51891/rease. v7i8.1984.
Adam, A. M. A., Saad, H. A., Alsuhaibani, A. M., Refat, M. S., & Hegab, M. S. (2021). Química de transferência de carga da azitromicina, o antibiótico usado mundialmente para tratar a doença do coronavírus (Covid-19). Parte III: Um protocolo verde para síntese fácil de complexos com aceitadores TCNQ, DDQ e TFQ., Jornal de moléculas líquidas, Elsevier.355(1), 1-12.
Berson, L. R. S. (2020). ZitromaxIV azitromicinadi-hidratada. Wyeth Indústria Farmacêutica Ltda.7(80)1-5 21. doi.org/10.51891/rease. v7i8.1984.
Baptista, M. G. F. M. (2013). Mecanismos de Resistência aos Antibióticos,monografia (Dissertação de Mestrado) Curso de Mestrado Integrado em Ciências Farmacêuticas, Universidade Lusófona de Humanidades e Tecnologia, Lisboa. 42.
Braz., H.., et al. (2020). Estudo in silico da azitromicina, cloroquina e hidroxicloroquina e seus potenciais mecanismos de ação contra a infecção por SARS-CoV-2.7(6), 56547-56556. 10.34117/bjdv7n6-18
Blair, J. M. et, al. (2017). Molecular Mechanisms of Antibiotic Resistance. Nature. 13(2), 42- 51. 10.18468/estcien. 2017v7n2.p45-57.
Bosseboeuf, E., Aubry, M., Nhan, T., Pina, J. J., Rolain, J. M., Raoul, T. D. et al. (2018).Azithromycin Inhibits the Replication of Zika Virus. J Antivir Antiretrovir. 10(6) 6-11. 10.4172/1948-5964.1000173.
Colson, P., et, al. Chloroquine and hydroxychloroquine as available weapons to fight Covid-19. Int J Antimicrob Agents. 55(4),105-932.
Costa., Anderson Luiz., Silva Junior., Antonio Carlos Souza. (2016) Resistência bacteriana aos antibióticos e Saúde Pública: uma breve revisão de literatura. Estação Científica (UNIFAP), Macapá. 7(2),45-57.
Calderón, J. L. M., Márquez, F. C. L., & Flores. (2018). PR.Azitromicina como tratamento contra Chlamydia trachomatis?Centro de Pesquisa Biomédica – Mexico. 154 (6), 689-69.
Davidson, R.J. (2019) In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections. Infect Drug Resist. 12:585.
Ferracini, F. T., Filho, W. M. B., & Almeida, S.M. (2014) Atenção à Prescrição Médica, Atheneu.P.53
Fuchs, F. D.; & Wannmacher, L. (2010). Farmacologia Clínica: fundamentos da terapêutica racional. (4a ed.), Guanabara Koogan.P 55.
Fantini, J., Chahinian, H., Yahi, N. (2020) .Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. International Journal of Antimicrobial Agents. 7(6), 56547-56556. 10.34117/bjdv7n6-18
Guimarães, D. O., Momesso, L. S., Pupo, M. T. (2010). Antibióticos: Importância Terapêutica e Perspectivas para a Descoberta de Novos Agentes. Química Nova. 33(30), 667- 679. 10.18468/estcien. 2017v7n2.p45-57.
Gautret, et al. (2020) Hydroxychloroquine and azithromycin as a treatment of Covid19: results of an open-label non-randomized clinical trial. Ed.1, P.105 949.
Holmes, A. H., Moore, L. S., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., et, al. (2016). Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 387(10014),176-87.
Iriarte, D. F. (2020) Resistência bacteriana aosmacrolídeos: um olhar sobre a azitromicina.monografia, SãoCartos:Universidade Federal de São Carlos.7(8),19-84. doi.org/10.51891/rease. v7i8.1984.
Júnior, A. M. (2019). Multirresistência a antibióticos em hospitais. ScireSalutis. 9(2), 1-8.
Kelleni, M. (2020). Nitazoxanide/Azithromycin combination for Covid-19: A suggested new protocol for Covid-19 early management. Pharmacological Research, 157(2) 104-874.
Michael, J., et al. (2014). Azithromycin: Mechanisms of action and their relevance for clinical applications, Pharmacology & Therapeutics.143(2),225-245.
Meireles, M. A. O. M. (2008). Uso de Antimicrobianos e Resistência Bacteriana: Aspectos Socioeconômicos e Comportamentais e seu Impacto Clínico e Ecológico. 7(2) ,47. 10.18468/estcien.
Marquioti, C. M. J., Lanes, L. C., & Castro, G. F. P. (2015). Uso irracional de antibióticos na infância: contribuição do profi ssional farmacêutico para a promoção da saúde. Rev transformar. [citado em 20 fev. 2016]. 13(3),39-77.
Moreno, K. M. M. (2013). Carbapenêmicos: tipos y mecanismos de resistência bacterianos. Rev Med Costa Rica y Centroamericana. 608(8), 599-605.
Neto, I. F. S., Ricardino, I. E. F., Souza, M. N. C., & Mendes, R. C., (2020) Alvos moleculares dos Fármacos no tratamento da Covid-19. Cadernos de prospecção – Salvador. 13(5), 1251-1271.
Oliveira, A. C., & Silva, R. S. (2008). Desafios do Cuidar em Saúde Frente à Resistência Bacteriana: Uma Revisão. Revista Eletrônica de Enfermagem. 1(10), 189-197.
Opa-Oms., Anvisa. (2007). Medidas de prevenção e controle da resistência Microbiana e programa de uso racional de antimicrobianos em serviços de saúde – RM controle.
Opal, S. M., & Pop-Vicas, A. (2015). Molecular mechanisms of antibiotic resistance in bacteria. In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases / [editedby] John E. Bennett, Raphael Dolin, Martin J. Blaser. – Eighth edition. Philadelphia: Elsevier. 234-251.
Oliveira,R & Aires ,T.(2016). Resistência aos antibacterianos. Artigo de revisão Gazeta Médica. 3(2), 14-21.
Pereira, A. S. et al. (2018). Metodologia da pesquisa científica. Santa Maria: UAB/NTE/UFSM.9(9). http://dx.doi.org/10.33448/rsd-v9i9.7245
Pani, A., Lauriola, M., Romandini, A., & Scaglione, F. (2020). Macrolídeos e infecções virais: enfoque na azitromicina na patologia de Covid-19., Jornal internacional de agentes antimicrobianos.56(2), 1-18.
Rang, H. P., & Dale, M. M. (2016). Editora Elsevier, 8aedição, 2016. Farmacologia Clínica. Fuchs, F.D.; Wannmacher, L. Editora Guanabara Koogan.4°ed, P55.
Uzunian, A. (2020). Coronavirus SARS-CoV-2 and Covid-19. Jornal Brasileiro de Patologia e Medicina Laboratorial, 56(4).
Vieira, P. N, & Vieira, S. L. V. (2017). Uso irracional e resistência a antibióticos em hospitais. Arquivos de ciências e da saúde da UNIPAR. 21(3), 209-212.
Wong, A. (2020). Covid-19 e toxidade de tratamentos potenciais: panaceia ou veneno. EMA Medicina de Emergência Australasia. 32(1), 697-699.
Wang, X. et, al. (2020). Nosocomial outbreak of Covid-19 pneumonia in Wuhan, China. European Respiratory Journal. 55(60).
Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of theCytokineStorm'in Covid-19. Journal of infection, 80(6), 607-13.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Marinete Sousa Freires; Omero Martins Rodrigues Junior
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
